The article discusses the prolonged median progression-free survival by the phase 3 RADIANT-4 trial in patients with (G1/G2) nonfunctional neuroendocrine tumours (NET) of gastrointestinal or bronchopulmonary origin. Topics include the result shown in patients with GI NET months in the everolimus and in the placebo group, the risk reduction seen in patients with NET of unknown primary, and the need to consider everolimus in metastatic NET of Gl origin.